AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Vir Biotechnology Inc (NASDAQ:VIR)
5.265 USD
+0.015 0.286%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.25 |
|---|---|
| Change | +0.015 0.286% |
| 52 W H/L (in USD) | 27.480/7.610 |
| EBITDA (in USD) | -578.403M |
| PE Ratio | -- |
| Volume | 358982 |
| Diluted Eps TTM | -4.08 |
| Total Assets (in USD) | 1960.09M |
|---|---|
| Total Liabilities (in USD) | 369.854M |
| Revenue TTM (in USD) | 79.599M |
| Cash (in USD) | 254.844M |
| Market Cap (in USD) | 1,459.913 M |
| Revenue Per Share TTM | 0.592 |
| Gross Profit TTM (in USD) | 1032.03M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Employees: 587
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. George A. Scangos Ph.D. | Pres, CEO & Director | 1948 |
| 2. | Mr. Howard Horn | Exec. VP, CFO & Sec. | 1978 |
| 3. | Dr. Ann M. Hanly Ph.D. | Exec. VP & Chief Technology Officer | 1970 |
| 4. | Dr. Phillip Pang M.D., Ph.D. | Exec. VP, Chief Medical Officer & Interim Head of Research | 1975 |
| 5. | Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 1960 |
| 6. | Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | NA |
| 7. | Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | NA |
| 8. | Ms. Johanna Friedl-Naderer | Exec. VP & COO | 1968 |
| 9. | Mr. Steven J. Rice | Exec. VP & Chief Admin. Officer | 1960 |
| 10. | Ms. Heather Rowe Armstrong | VP of Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+2.110 2.680% | 80.64 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.400 3.073% | 79.1 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+6.680 1.476% | 453.19 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+5.420 1.045% | 517.23 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 754.28M | 549.802M | -298.611M | -174.529M | -116.364M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | 515.837M | 528.584M | -298.665M | -174.683M | -115.884M |
| Selling General Administrative | 161.762M | 160.793M | 70.937M | 37.598M | 29.131M |
| Gross Profit | 1434.153M | 1021.203M | 76.368M | 0.711M | 10.668M |
| Reconciled Depreciation | 6.783M | 5.811M | 5.442M | 4.517M | 2.756M |
| Ebit | 833.068M | 276.891M | -298.719M | -182.496M | -118.692M |
| Ebitda | 944.208M | 282.702M | 514.328M | -177.979M | -115.936M |
| Depreciation And Amortization | 111.14M | 5.811M | 5.442M | 4.517M | 2.756M |
| Operating Income | 833.068M | 276.891M | -296.98M | -177.979M | -118.692M |
| Other Operating Expenses | 747.404M | 666.317M | 373.348M | 178.69M | 119.56M |
| Interest Expense | 183.145M | 272.911M | 3.811M | 7.967M | 0M |
| Tax Provision | 238.443M | 21.218M | 0.054M | 0.154M | -0.48M |
| Interest Income | 28.092M | 0.439M | 2.836M | 8.511M | 2.54M |
| Net Interest Income | 28.092M | 0.439M | 2.836M | 8.511M | 2.54M |
| Income Tax Expense | 238.443M | 21.218M | -0.054M | 0.154M | -0.48M |
| Total Revenue | 1580.472M | 1087.068M | 76.368M | 0.711M | 0.868M |
| Total Operating Expenses | 601.085M | 600.452M | 373.348M | 178.69M | 119.56M |
| Cost Of Revenue | 146.319M | 65.865M | - | 143.072M | -9.8M |
| Total Other Income Expense Net | -78.788M | 272.911M | 296.681M | 3.45M | -0.212M |
| Net Income From Continuing Ops | 515.837M | 528.584M | -298.665M | -174.683M | -115.884M |
| Net Income Applicable To Common Shares | 515.837M | 528.584M | -298.665M | -174.683M | -115.884M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1960.09M | 2802.088M | 1954.268M | 918.761M | 512.071M |
| Intangible Assets | 22.592M | 32.755M | 33.287M | 33.82M | 35.694M |
| Other Current Assets | 40.949M | 104.356M | 73.003M | 27.511M | 13.378M |
| Total Liab | 369.854M | 724.125M | 522.419M | 201.909M | 88.129M |
| Total Stockholder Equity | 1590.236M | 2077.963M | 1431.849M | 716.852M | 423.942M |
| Other Current Liab | 91.353M | 484.953M | 232.585M | 83.646M | 46.907M |
| Common Stock | 0.013M | 0.013M | 0.013M | 0.013M | 0.011M |
| Capital Stock | 0.013M | 0.013M | 0.013M | 0.013M | 0.011M |
| Retained Earnings | -237.824M | 377.237M | -138.6M | -667.184M | -368.519M |
| Good Will | 16.937M | 16.937M | 16.937M | 16.937M | 16.937M |
| Other Assets | 0M | 21.226M | 9.781M | 77.693M | 9.247M |
| Cash | 254.844M | 848.631M | 347.815M | 436.575M | 109.335M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 175.407M | 511.029M | 341.242M | 99.064M | 59.206M |
| Current Deferred Revenue | 64.853M | 15.517M | 98.209M | 6.451M | 6.181M |
| Net Debt | -130.304M | -720.657M | -214.254M | -370.019M | -109.098M |
| Short Term Debt | 12.867M | 4.137M | 3.927M | 3.89M | 0.237M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 124.54M | 127.974M | 133.561M | 66.556M | 0.237M |
| Other Stockholder Equity | 1828.862M | 1709.835M | 1571.535M | 1385.301M | 280.98M |
| Property Plant Equipment | - | 188.166M | 130.054M | 17.946M | 16.308M |
| Total Current Assets | 1588.226M | 2519.077M | 1562.821M | 772.365M | 402.995M |
| Long Term Investments | 105.275M | 23.927M | 201.388M | 0M | 24.29M |
| Short Term Investments | 1280.833M | 1553.409M | 360.33M | 300.286M | 274.101M |
| Net Receivables | 11.6M | 26.4M | 773.079M | 1.9M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | 8.594M | - | - |
| Accounts Payable | 6.334M | 6.422M | 6.521M | 5.077M | 5.881M |
| Accumulated Other Comprehensive Income | -0.815M | -9.122M | -1.099M | -1.278M | -0.601M |
| Non Currrent Assets Other | 12.382M | 21.226M | 9.781M | 15.746M | 15.847M |
| Non Current Assets Total | 371.864M | 283.011M | 391.447M | 146.396M | 109.076M |
| Capital Lease Obligations | 124.54M | 123.837M | 133.561M | 70.446M | 0.237M |
| Long Term Debt Total | - | - | - | - | 0.9M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -1193.461M | -118.997M | -3.493M | -256.158M | -60.441M |
| Total Cashflows From Investing Activities | -1193.461M | -140.814M | -9.862M | -256.158M | -60.441M |
| Total Cash From Financing Activities | 34.761M | 100.331M | 529.474M | 449.244M | 24.978M |
| Net Income | 515.837M | 528.584M | -298.665M | -174.683M | -115.884M |
| Change In Cash | 504.553M | -88.072M | 328.671M | 63.454M | -129.559M |
| Begin Period Cash Flow | 363.415M | 451.487M | 122.816M | 59.362M | 188.921M |
| End Period Cash Flow | 867.968M | 363.415M | 451.487M | 122.816M | 59.362M |
| Total Cash From Operating Activities | 1663.253M | -47.589M | -190.941M | -129.632M | -94.096M |
| Depreciation | 6.783M | 5.811M | 5.442M | 4.517M | 2.756M |
| Other Cashflows From Investing Activities | - | - | 0.18M | 0.18M | 0.18M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | 52.815M | - | - | 0M |
| Sale Purchase Of Stock | 3.222M | 15.377M | 327.273M | -0.003M | 14.838M |
| Other Cashflows From Financing Activities | 3.337M | 15.377M | -0.189M | 322.931M | 24.978M |
| Capital Expenditures | 68.028M | 21.817M | 6.549M | 8.94M | 8.192M |
| Change In Working Capital | 665.367M | -628.394M | 29.522M | 8.204M | 12.494M |
| Other Non Cash Items | 388.37M | -52.56M | 45.212M | 8.947M | 1.965M |
| Free Cash Flow | 1595.225M | -69.406M | -197.49M | -138.572M | -102.288M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 1 year ago | 5787620 |
| 2. | Scottish Mortgage Ord | 1 year ago | 3798150 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 3457160 |
| 4. | SPDR® S&P Biotech ETF | 1 year ago | 3410932 |
| 5. | Vanguard Small Cap Index | 1 year ago | 2736536 |
| 6. | iShares Russell 2000 ETF | 1 year ago | 1961600 |
| 7. | Vanguard Small Cap Growth Index Inv | 1 year ago | 1546766 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1338104 |
| 9. | iShares S&P Small-Cap 600 Value ETF | 1 year ago | 1050192 |
| 10. | Fidelity Small Cap Index | 1 year ago | 851895 |
| 11. | SPDR® Portfolio S&P 600 Sm Cap ETF | 1 year ago | 765759 |
| 12. | iShares Russell 2000 Value ETF | 1 year ago | 736342 |
| 13. | Vanguard Tax-Managed Small Cap Adm | 1 year ago | 669971 |
| 14. | iShares Biotechnology ETF | 1 year ago | 649741 |
| 15. | SPDR® S&P 600 Small Cap Value ETF | 1 year ago | 576393 |
| 16. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 528058 |
| 17. | Fidelity Extended Market Index | 1 year ago | 509050 |
| 18. | Bridgeway Small Cap Value | 1 year ago | 473800 |
| 19. | Bridgeway Small-Cap Value | 1 year ago | 473800 |
| 20. | EA Bridgeway Omni Small-Cap Value ETF | 1 year ago | 469273 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 16864579 |
| 2. | SB INVESTMENT ADVISERS (UK) LTD | 1 year ago | 16684041 |
| 3. | Vanguard Group Inc | 1 year ago | 12297139 |
| 4. | State Street Corporation | 1 year ago | 6912082 |
| 5. | Baillie Gifford & Co Limited. | 1 year ago | 3947065 |
| 6. | AllianceBernstein L.P. | 1 year ago | 2781049 |
| 7. | Morgan Stanley - Brokerage Accounts | 1 year ago | 2126279 |
| 8. | Geode Capital Management, LLC | 1 year ago | 1886396 |
| 9. | Bill & Melinda Gates Foundation | 1 year ago | 1559142 |
| 10. | Bridgeway Capital Management, LLC | 1 year ago | 1343904 |
| 11. | Renaissance Technologies Corp | 1 year ago | 1294600 |
| 12. | Goldman Sachs Group Inc | 1 year ago | 1155514 |
| 13. | Northern Trust Corp | 1 year ago | 937304 |
| 14. | Charles Schwab Investment Management Inc | 1 year ago | 753073 |
| 15. | Bank of New York Mellon Corp | 1 year ago | 720898 |
| 16. | UBS Group AG | 1 year ago | 526180 |
| 17. | Dimensional Fund Advisors, Inc. | 1 year ago | 468319 |
| 18. | Prudential Financial Inc | 1 year ago | 465489 |
| 19. | Principal Financial Group Inc | 1 year ago | 462030 |
| 20. | Barclays PLC | 1 year ago | 444694 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...